Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP7 | P09237 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27798969 | 0.87 | KDM4E (0.41) | ALDH1A1KDM4EHPGDGAACA2 | |
| SCHEMBL29497677 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDGAACA2 | |
| SCHEMBL20582868 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDGAACA2 | |
| SCHEMBL6901293 | 0.81 | ALDH1A1 (0.41) | ALDH1A1KDM4EHPGDGAACA2 | |
| SCHEMBL2295646 | 0.80 | HTR1D (0.43) | CA2 | |
| SCHEMBL2761579 | 0.80 | KDM4E (0.39) | ALDH1A1KDM4EHPGDGAACA2 | |
| SCHEMBL2290303 | 0.79 | MEN1 (0.50) | ALDH1A1HPGDGAACA2CA12 | |
| SCHEMBL6409631 | 0.77 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDGAACA2 | |
| SCHEMBL2293507 | 0.77 | HTR2A (0.37) | KDM4ECA2CA12SMN1; SMN2LMNA | |
| SCHEMBL1058869 | 0.76 | HTR2A (0.44) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149545-B1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-7994367-B2 | Method for producing benzaldehyde compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100210879-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2149545-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
| US-6562823-B1 | Inhibition of farnesyl-protein transferase has been shown to block the growth of Ras-transformed cells in soft agar | MERCK & CO., INC. | 2003-05-13 | — | — | US | disclosed |
| US-6441017-B1 | Inhibitors of prenyl-protein transferase | MERCK & CO., INC. | 2002-08-27 | — | — | US | disclosed |
| US-6413964-B1 | 14-AMINO-14-(1-METHYL-1H-IMIDAZOL-5-YL)-8-OXA-2-THIA-1,18 -DIAZATETRACYCLO(16.2.2.1(3,7).1(9,13))TETRACOSA-3(24),4,6, 9(23),10,12-HEXAENE-10-CARBONITRILE 2,2-DIOXIDE, FOR EXAMPLE; USE IN RADIOTHERAPY, CHEMOTHERAPY AS SENSITIZER | MERCK & CO., INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1214326-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001017992-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2001018006-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000025789-A1 | A METHOD OF TREATING ENDOMETRIOSIS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210879-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | NQO1, C9, TRPA1 | ALDH1A1 83/4885KDM4E 1499/4885HPGD 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.